Log in


NLRC4 Mutation and XIAP Deficiency:
The Swiss-based company AB2 Bio is conducting a clinical study in North America (U.S.A. and Canada), and recruiting patients in several regions. The aim of this Phase III study is to assess the efficacy and safety of Tadekinig alfa in patients with monogenic, interleukin-18 driven autoinflammation caused by NLRC4-MAS mutation or XIAP deficiency.

More information about the study can be found on the Study Info Sheet,  Press Release or the entry on ClinicalTrials.gov.

Office: +1 (856) 589-6606
Fax: +1 (856) 589-6614
Email: secretariat@histiocytesociety.org

Histiocyte Society
332 N Broadway
Pitman, NJ 08071 USA

Powered by Wild Apricot Membership Software